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and differentiate them from other conditions in order to
institute the appropriate treatment, if this is possible.
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Fludarabine: risk factor for
aggressive behaviour of squamous
cell carcinoma of the skin?
Fludarabine, a purine analogue, is effective in the therapy of
low-grade non-Hodgkin’s lymphomas. Side-effects include
fever, peripheral neuropathy, pulmonary toxicity and signifi-
cant depletion of T-lymphocyte populations. In addition, flare
up and aggressive behaviour of squamous cell carcinoma
(SCC) during fludarabine therapy has been observed [1].
We report on a 65-year-old patient with a lymphocytic B-
cell lymphoma (stage IVA) diagnosed in 1997. Owing to an
excess of blasts he was treated according to the German con-
sensus protocol for aggressive non-Hodgkin’s lymphoma.
However, three cycles of CHOEP (cyclophosphamide, doxoru-
bicin, vincristine, etoposide and prednisone) chemotherapy
and two cycles of salvage therapy with holoxane, cytosar and
vepeside did not produce a response, and led to complications
such as Candida esophagitis and generalised herpes zoster
infection. Owing to progressive lymphadenopathy and
lymphocytosis, the patient was treated with four cycles of
chlorambucil and prednisone, showing again minimal
response. In 2001, six cycles of fludarabine led to a near
complete remission with reduction of all lymph node manifes-
tations and normalisation of peripheral lymphocyte counts.
Since the patient’s disease progressed again, a combined
immunochemotherapy with rituximab and fludarabine was
initiated in autumn 2002. Again, a near complete clinical
remission was achieved. However, within 2 weeks of the
fourth therapy cycle, the patient developed a well-circum-
scribed nodule on the right cheek. The tumour impressed with
a diameter of 1 cm and a centrally located horn plug.
Histology showed a well demarcated invasive proliferation
of epithelial cells with squamous differentiation, extending
into the dermis, a perineural invasion by tumour cells and
lymphohistiocytic infiltration at the margins of the neoplasm.
Immunohistochemistry revealed that the majority of the infil-
trating lymphocytes were CD3+ CD4+ T-helper cells, whereas
a few cells expressed CD8 antigen. Complete excision of the
lesion was conducted and confirmed by micrographic work-up
of the specimen. Two months later the patient presented with
regrowth of the tumour. Again, total excision was performed
resulting in two further recurrences within the following 3
months. Nine months after local consolidating radiotherapy
(51 Gy) no further recurrence had occurred.
Although differential diagnosis of keratoacanthoma was
considered initially, the histological features of perineural
invasion and infiltrative tumour strands, as well as repeated
tumour recurrence, strongly suggested the diagnosis of SCC
[2, 3]. However, aggressive behaviour of the tumour led to
the question of whether in this immunocompromised patient
human papilloma viruses (HPV), especially HPV 5 and 8,
might be involved in the development and unusual clinical
course of skin cancer [4]. Accordingly, we performed a
nested PCR, but did not detect the suspected HPV-specific
sequences in the biopsy tissue. Non-Hodgkin’s lymphomas
on their own or fludarabine may be responsible for the
increased incidence and aggressive behaviour of SCC in
these patients [5]. Thus, we assume that the altered immune
status in this patient was aggravated by concomitant fludara-
bine-induced T-lymphocyte depletion, which thereby facili-
tated the growth and aggressive behaviour of this secondary
malignancy [6]. Careful examination of patients at risk will
be warranted in order to detect secondary malignancies
early and to treat them extensively.
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Can HER2 overexpression predict
response to pegylated liposomal
doxorubicin in metastatic breast
cancer patients?
We conducted a phase II clinical trial to determine the clinical
efficacy and safety of pegylated liposomal doxorubicin in
combination with gemcitabine as a first- or second-line treat-
ment option in patients with metastatic breast cancer [1].
Based on a previous phase II study [2], the recommended
dose was pegylated liposomal doxorubicin 25 mg/m2 intra-
venously (i.v.) on day 1 and gemcitabine 800 mg/m2 i.v. on
days 1 and 8, every 21 days. A total of 41 patients were
entered into the study between February 2003 and April 2004.
The demographic and baseline clinical characteristics of all
patients are listed in Table 1. Forty-one patients were assessa-
ble for response. The overall objective response rate (ORR)
was 51% [95% confidence interval (CI) 35.9% to 66.5%],
with one complete response (CR) (2.5%) and 20 partial
responses (PRs) (48%). Eleven patients (27%) had evidence of
stable disease (SD), and the remaining nine patients had dis-
ease progression (22%).
Nineteen women had HER2-overexpressing (2+/3+; Dako
Herceptest) breast tumors, while in the other 19 patients breast
cancer did not overexpress HER2 (0/1+). HER2 overexpres-
sion score 2+ showed amplification at the DNA level detected
by fluorescence in situ hybridization. In three patients HER2
expression was not assessed. Concerning patients with HER2-
positive tumors, 68% experienced a response (13 patients; one
CR and 12 PRs), while 15.7% had evidence of SD (three
patients) and 15.7% (three patients) had disease progression.
Conversely, among women with HER2-negative tumors, the
ORR was half that observed in HER2-positive cases (31.5%,
all PRs), with a rate of SD and PD of 42% (eight patients) and
26% (five patients), respectively. Sixty-one per cent of
patients with HER2-positive disease were endocrine responsive
(estrogen receptor and/or progesterone receptor positive
tumors). Among 13 women who achieved a response to pegy-
lated liposomal doxorubicin plus gemcitabine combination,
seven were chemotherapy naı¨ve for metastatic disease, while
six had previously received chemotherapy. Responses were
also observed in six out of 13 patients with previous anthracy-
cline exposure, with a PR rate of 46%.
No data on the predictive value of HER2 expression regard-
ing response to gemcitabine in breast cancer are currently
available. It has been reported that the gemcitabine–cisplatin
interaction is more active than the etoposide–cisplatin inter-
action in lung cancer cells with high p185neu expression [3].
Elevated levels of HER2 extracellular domain adversely affect
the efficacy of paclitaxel plus gemcitabine in advanced breast
carcinoma [4].
Our findings seem to support, even considering the low
number of patients recruited, a positive interaction between
HER2 overexpression and sensitivity to pegylated liposomal
doxorubicin, substantially confirming the sensitivity of
Table 1. Characteristics of the patients
Characteristic
Total patients 41
Median age, years (range) 55 (33–71)
Pre-/post-menopausal status 4/37
Hormonal receptor status
ER+/PgR+ 21
ER/PgR 16
ER+/PgR 3
ER/PgR+ 1
Grading
Grade 1 6
Grade 2 15
Grade 3 20
HER 2 (Dako Herceptest)
0/1+ 19 (14/5)
2+/3+ 19 (9a/10)
Unknown 3
Predominant metastatic sites
Visceral 34
Bone/soft tissues 7
No. of metastatic site
1 30
$2 11
Previous anthracycline treatment 13
Adjuvant 9
Metastatic 4
aAmplification at DNA level detected by fluorescence in situ
hybridization.
ER, estrogen receptor; PgR, progesterone receptor.
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